Arcutis Earnings Call Signals Momentum Amid Headwinds

Arcutis Biotherapeutics Inc ((ARQT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Arcutis Biotherapeutics struck a cautiously upbeat tone on its latest earnings call, highlighting robust prescription momentum, strong year-over-year revenue growth, and a clear path to pipeline-driven expansion. Management acknowledged a seasonally soft first quarter and ongoing pricing pressure, but emphasized positive cash flow, market share gains, and investments meant to unlock a larger growth inflection starting in 2026 and accelerating into 2027.

Strong Revenue Growth and Demand Fundamentals

Arcutis reported Q1 2026 net product revenue of $105.4 million, a 65% increase versus the prior year as more patients started and stayed on therapy. Management attributed the performance to rising demand for ZORYVE and better gross-to-net dynamics, even as overall category softness and winter weather held back sequential growth.

Sustained Prescription Momentum into Q2

ZORYVE averaged roughly 21,000 prescriptions per week in the quarter on a rolling four-week basis, underscoring steady utilization by prescribers. Early Q2 trends look encouraging, with scripts through April 24 running about 13% above the same period in Q1, suggesting demand is already rebounding from seasonal weakness.

Market Share Gains in Non-Steroidal Topicals

Within branded non-steroidal topical therapies, ZORYVE’s share climbed to 48% in Q1, up three percentage points from late 2025, indicating continued share capture despite a softer category backdrop. New-to-brand prescriptions also reached 48% share in this segment, reinforcing the drug’s position as a preferred option for new patients.

Gross-to-Net Trends Gradually Improving

Gross-to-net remained in the 50% range but improved versus Q1 2025, aided by better formulary positioning and contracting progress. Management expects gross-to-net to move from the high-50s early in the year toward the low-50s by the end of 2026, still a significant drag but directionally supportive of margin expansion.

Maintained Full-Year Revenue Guidance Range

Despite Q1’s sequential dip, Arcutis reaffirmed its 2026 revenue guidance of $480 million to $495 million, signaling confidence in the demand trajectory. Executives pointed to seasonal and weather factors as temporary headwinds and said they expect net sales to resume quarter-over-quarter growth in Q2 as underlying trends remain strong.

Turning the Corner to Positive Operating Cash Flow

The company generated $2.2 million of net cash from operating activities in Q1 and ended March with $224.3 million in cash and marketable securities, providing a solid liquidity cushion. Management guided to maintaining positive quarterly operating cash flow through 2026, even as it funds commercial expansion and a broadening R&D pipeline.

Commercial Build-Out in Dermatology and Beyond

Arcutis completed its dermatology sales force expansion, with new representatives already in the field and expected to contribute more visibly from Q3 onward. The company is also constructing a targeted primary care and pediatric team under newly hired leadership, with meaningful influence on prescriptions anticipated in late 2026 and into 2027.

Pediatric and Infant Label Expansion Strategy

In April, the company submitted a supplemental NDA seeking to extend ZORYVE cream 0.05% to infants aged 3 to 24 months with atopic dermatitis, coming just three months after topline infant trial results. Management views pediatric and infant approvals as a key growth lever that can broaden the franchise and deepen penetration among younger patients.

Compelling INTEGUMENT Infant Trial Outcomes

The INTEGUMENT infant Phase II study produced what Arcutis described as compelling efficacy and rapid symptom relief, with over one-third of infants meeting stringent VIGA-AD success criteria by week four and more than half rated clear or almost clear. Roughly 58% achieved EASI-75 at week four, and many experienced meaningful itch relief within minutes to hours, which could resonate strongly with parents and physicians.

Regulatory Progress in Pediatric Psoriasis

The company finished enrolling the MUSE trial evaluating ZORYVE foam 0.3% in children aged 2 to 11 with scalp and body psoriasis, adding another potential pediatric indication. Separately, a supplemental NDA to expand ZORYVE cream 0.3% down to age two is under FDA review, with a decision deadline set for late June and the potential to further extend the drug’s reach in psoriasis.

Pipeline Advancement with ARQ-234

Arcutis initiated a Phase I study of ARQ-234, a CD200R agonist, beginning with single-ascending dose testing in healthy volunteers and planning subsequent multiple-dose and proof-of-concept cohorts in moderate-to-severe atopic dermatitis. Management framed ARQ-234 as an important step toward diversifying beyond ZORYVE and building a longer-term immunology franchise.

Multiple Proof-of-Concept Trials Underway

Phase II proof-of-concept programs for ZORYVE in vitiligo and hidradenitis suppurativa continue to enroll, giving investors a pipeline of potential catalysts. The company expects a vitiligo data readout in the fourth quarter of 2026 and a hidradenitis suppurativa update in the first quarter of 2027, which could open additional specialty-dermatology markets if successful.

Seasonality and Weather-Driven Volume Pressure

First-quarter revenue fell sequentially from Q4, as is typical, but this year’s decline was amplified by severe weather that depressed dermatology visits and prescriptions. ZORYVE scripts fell about 6% quarter over quarter, yet the drug still outperformed peers as branded non-steroidal topicals collectively dropped roughly 15%, highlighting relative resilience.

Rising Operating Expenses to Fund Growth

Operating costs stepped up sharply, with SG&A rising 16% year over year to $74.1 million as the company invested in commercial infrastructure and marketing. R&D spending climbed to $30.6 million, driven largely by a $10 million milestone payment linked to dosing ARQ-234, underscoring Arcutis’s commitment to pipeline advancement even as it manages profitability.

Persistent Gross-to-Net and Access Headwinds

Despite gradual improvement, gross-to-net concessions remain substantial in the 50% range, reflecting heavy discounting and patient support programs that weigh on realized revenue. Additionally, ZORYVE currently has coverage in roughly one-third of Medicare Part D plans, and management signaled that achieving broad Part D access will be a multi-year effort stretching toward 2027.

Limited Near-Term Payoff from Sales Force Expansion

While the expanded dermatology sales team is now deployed, executives cautioned that the bulk of their impact will show up from the third quarter onward, not immediately. The forthcoming primary care and pediatric effort is also expected to ramp gradually, suggesting investors should view these investments as setting up a 2026 and 2027 inflection rather than rapid near-term acceleration.

Balance Sheet Leverage and Financing Options

Arcutis carries $101.5 million of debt but also retains an option to draw an additional $50 million in committed financing through mid-2026, providing flexibility if market conditions shift. Management framed the current balance between modest leverage, positive operating cash flow, and ample cash reserves as sufficient to execute its growth and development plans.

Broader Category Weakness Weighing on Volumes

The company noted that prescription softness extended beyond its own products, with topical steroids, antifungals, vitamin D analogs, and calcineurin inhibitors all showing volume declines in Q1. This broader downturn suggests macro or channel-driven factors played a meaningful role in the quarter’s slow start and may normalize as patient visits pick up.

Forward-Looking Guidance and Outlook

Management reiterated its full-year 2026 revenue outlook of $480 million to $495 million and guided to quarter-over-quarter net sales growth beginning in Q2, underpinned by rising prescriptions and share gains. They expect gross-to-net to stay in the 50% band but to trend lower, anticipate modest SG&A increases in the second half to support sales force builds, and aim to remain cash-flow positive while pursuing pipeline milestones and label expansions.

Arcutis’s latest earnings call painted a picture of a company navigating near-term headwinds while laying groundwork for multi-year growth, fueled by ZORYVE’s momentum and a steadily advancing pipeline. Investors will be watching closely to see if improving prescription trends, pediatric approvals, and new indications can overcome persistent pricing and access challenges and push results toward the upper end of guidance.